MEK/ERK-dependent regulation of TFEB in response to chemotherapeutic stress (AACRPanCa 2026) - Oct 15, 2026 - Abstract #B041; "Consistent with a protective role for this pathway, co-treatment with the MEK inhibitor trametinib enhanced the growth-inhibitory effects of gemcitabine in PDM-41 organoids. In parallel, as previously reported, we observed that gemcitabine and CX-5461 induced an electrophoretic mobility shift of TFEB, indicative of changes in TFEB phosphorylation, although less pronounced than that induced by the mTOR inhibitor Torin1...In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026; 86(18_Suppl_2):Abstract nr B041."
Pancreatic Cancer • Solid Tumor • TFEB
|
|
Marie-Josee Boucher; Marjorie Rolland
|